Pharmamar ... A Destacar en ESMO19 : “SAKK 17/16: Lurbinectedin as Second or Third Line Palliative Chemotherapy in Malignant Pleural Mesothelioma (MPM): A Multi-center, single-arm Phase II trial”. Llevado a cabo por SAKK con la colaboración de PharmaMar .